Ocuphire Pharma
zeta phase design placebo bid day | Ocuphire Pharma
Company
Deck Type
Deck date
January 2023
Slide
8 of 31
Related slides by other companies
BenevolentAI
Results
March 2023
ben indicative data from phase caveats phase was not powered to meaningfully assess only patients dosed with active per group maximum duration of dosing days score changes typically measured at days mean change from affected in treated areas day bid | BenevolentAI
MindMed
Investor Presentation
December 2024
for gad phase program overview | MindMed
GH Research
Investor Presentation
March 2023
design of phase trial in | GH Research
GH Research
Investor Presentation
March 2023
phase efficacy | GH Research
Other recent decks by Ocuphire Pharma
See all presentations (10 decks)
Investor Presentation
November 2023
Investor Presentation
August 2023
Investor Presentation
May 2023
Results
October 2022
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights